SEARCH

SEARCH BY CITATION

References

  • African Programme for Onchocerciasis Control (2004) Year 2004 progress report of WHO/APOC. http://www.apoc.bf/en/download.htm .
  • African Programme for Onchocerciasis Control (2005) Report of the 20th session of the Technical Consultative Committee (TCC) Ouagadougou, 14–19 March 2005. http://www.apoc.bf/en/download.htm .
  • African Programme for Onchocerciasis Control (2006) Special meeting on sustainability of CDTI: final communiqué and recommendations, Ouagadougou, 2–5 February 2006. http://www.apoc.bf/en/download.htm .
  • African Programme for Onchocerciasis Control (2007) Community Directed Treatment with Ivermectin (CDTI): a pratical guide for trainers of Community Directed Distributors (CDDs). http://www.apoc.bf/en/CDTI .
  • Akogun OB, Akogun MK & Audu Z (2000) Community-perceived benefits of ivermectin treatment in northeastern Nigeria. Social Science and Medicine, 50, 14511456.
  • Amazigo U & Boatin B (2006) The future of onchocerciasis control in Africa. The Lancet, 368, 19461947.
  • Amazigo UV, Okeibunor JC, Matovu V, Zoure′ H, Bump J & Seketeli A (2007) Performance of predictors: evaluating sustainability in community directed projects of the African programme for onchocerciasis control. Social Science and Medicine, 64, 20702082.
  • Austin LT, Ahmad F, McNally MJ & Stewart DE (2002) Breast and cervical cancer screening in Hispanic women: a literature review using the health belief model. Women’s Health Issues, 12, 122128.
  • Borsboom GJ, Boatin BA, Nagelkerke NJ et al. (2003) Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West-Africa. Filaria Journal, 2, 8.
  • Brieger WR, Ramakrishna J, Adeniyi JD, Kale OO & Pearson CA (1986) Improving recognition of onchocerciasis in primary care – 2: learning from a cultural perspective. Tropical Doctor, 16, 913.
  • Brieger WR, Oke GA, Otusanya S, Azeez A, Tijani J & Banjoko M (1997) Ethnic diversity and disease surveillance: Guinea worm among the Fulani in a predominantly Yoruba district of Nigeria. Tropical Medicine and International Health, 2, 99103.
  • Brieger WR, Otusanya SA, Oke GA, Oshiname FO & Adeniyi JD (2002) Factors associated with coverage in community directed treatment with ivermectin for onchocerciasis control in Oyo State, Nigeria. Tropical Medicine and International Health, 7, 1118.
  • Brieger WR, Okeibunor JC, Abiose AO et al. (2007) Feasibility of measuring compliance to annual ivermectin treatment in the African PROGRAMME for onchocerciasis control. Tropical Medicine and International Health, 12, 260268.
  • Dao MYJ & Brieger WR (199495) Immunization for the migrant Fulani: identifying an underserved population in southwestern Nigeria. International Quarterly of Community Health Education, 15, 2132.
  • DiMatteo MR, Haskard KB & Williams SL (2007) Health beliefs, disease severity, and patient adherence: a meta-analysis. Medical Care, 45, 521528.
  • Emukah EC, Osuoha E, Miri ES, et al. (2004) A longitudinal study of impact of repeated mass ivermectin treatment on clinical manifestations of onchocerciasis in Imo State, Nigeria. American Journal of Tropical Medicine and Hygiene 70, 556561.
  • Farquharson L, Noble LM, Barker C & Behrens RH (2004) Health beliefs and communication in the travel clinic consultation as predictors of adherence to malaria chemoprophylaxis. British Journal of Health Psychology, 9 (Pt 2), 201217.
  • Finney Rutten LJ & Iannotti RJ (2003) Health beliefs, salience of breast cancer family history, and involvement with breast cancer issues: adherence to annual mammography screening recommendations. Cancer Detection and Prevention, 27, 353359.
  • Haselow NJ, Akame J, Evini C & Akongo S (2003) Programmatic and communication issues in relation to serious adverse events following ivermectin treatment in areas co-endemic for onchocerciasis and loiasis. Filaria Journal, 2(Suppl 1), S10.
  • Iliyasu Z, Kabir M, Abubakar IS, Babashani M & Zubair ZA (2005) Compliance to antiretroviral therapy among AIDS patients in Aminu Kano Teaching Hospital, Kano, Nigeria. Niger Journal of Medicine, 14, 290294.
  • IPSOR Medication Compliance and Persistence Special Interest Group (2006) Standardizing definition of terms. International Society for pharmacoeconomics and outcomes research. 2005. http://www.ispor.org/sigs/MCP_accomplishments.asp .
  • Kennedy MH, Bertocchi I, Hopkins AD & Meredith SE (2002) The effect of 5 years of annual treatment with ivermectin (Mectizan®) on the prevalence and morbidity of onchocerciasis in the village of Gami in the Central African Republic. Annals of Tropical Medicine and Parasitology, 96, 297307.
  • Lakwo TL & Gasarasi DB (2006) Non-adherence to community directed treatment with ivermectin for onchocerciasis control in Rungwe district, southwest Tanzania. East African Medical Journal, 83, 326332.
  • Lange LJ & Piette JD (2006) Personal models for diabetes in context and patients’ health status. Journal of Behavioral Medicine, 29, 239253.
  • Lee SH & Molassiotis A (2002) Dietary and fluid compliance in Chinese hemodialysis patients. International Journal of Nursing Studies, 39, 695704.
  • Maduka CU, Nweke LN, Miri ES, Amazigo U, Emukah EC & Richards FO (2004) Missed treatment opportunities, for pregnant and breast-feeding women, in onchocerciasis mass-treatment programmes in south-eastern Nigeria. Annals Tropical Medicine Parasitology, 98, 697702.
  • McDonald-Miszczak L, Maris P, Fitzgibbon T & Ritchie G (2004) A pilot study examining older adults’ beliefs related to medication adherence: the BERMA survey. Journal of Aging Health, 16, 591614.
  • Ndyomugyenyi R & Kabatereine N (2003) Integrated community-directed treatment for the control of onchocerciasis, schistosomiasis and intestinal helminths infections in Uganda: advantages and disadvantages. Tropical Medicine & International Health, 8, 9971004.
  • Ndyomugyenyi R, Tukesiga E, Buttner DWQ & Garms R. (2004) The impact of ivermectin treatment alone and when in parallel with Simulium naevei elimination on onchocerciasis in Uganda. Tropical medicine and International Health 9, 882886.
  • Nuwaha F, Okware J & Ndyomugyenyi R (2005) Predictors of compliance with community-directed ivermectin treatment in Uganda: quantitative results. Tropical Medicine & International Health, 10, 659667.
  • Orensky IA & Holdford DA (2005) Predictors of noncompliance with warfarin therapy in an outpatient anticoagulation clinic. Pharmacotherapy, 25, 18011808.
  • Plaisier AP, Alley ES, van Oortmarssen GJ, Boatin BA & Habbema JDF (1997) “Required duration of combined annual ivermectin treatment and vector control in the Onchocerciasis Control programme in West Africa”. Bulletin of the World Health Organization, 75, 237245.
  • Remme JHF (1997) Invitation to Investigators TDR, Geneva.
  • Rothova A, Van Der Lelij A, Stilma JS, Wilson WR & Barbe RF (1989) Side-effects of ivermectin in treatment of onchocerciasis. Lancet, 1, 14391441.
  • Russell KM, Perkins SM, Zollinger TW & Champion VL (2006) Sociocultural context of mammography screening use. Oncology Nursing Forum, 33, 105112.
  • Semiyaga NB, Lalobo O & Ndyomugyenyi R (2005) Refusal to take ivermectin: the associated ‘risk’ factors in Hoima district, Uganda. Annals of Tropical Medicine & Parasitology, 99, 165172.
  • Tielsch JM & Beeche A (2004) Impact of ivermectin on illness and disability associated with onchocerciasis. Tropical Medicine &International Health, 9, A45A56.
  • Turrisi R, Hillhouse J, Robinson J, Stapleton J & Adams M (2006) Influence of parent and child characteristics on a parent-based intervention to reduce unsafe sun practices in children 9 to 12 years old. Archieves Dermatology, 142, 10091014.
  • Winnen M, Plaisier AP, Alley ES et al. (2002) Can ivermectin mass treatments eliminate onchocerciasis in Africa? Bulletin of the World Health Organization;, 80, 384390.
  • Yirga D, Deribe K, Woldemichael K, Wondafrash M & Kassahun W (2010) Factors associated with compliance with community directed treatment with ivermectin for onchocerciasis control in Southwestern Ethiopia. Parasites & Vectors, 3, 48.
  • Yuan Y, L’italien G, Mukherjee J & Iloeje U (2006) Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Medicine, 7, 156162.